Bullish
Eli Lilly's Jaypirca approved by FDA for first-line CLL/SLL treatment
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults without known 17p deletion. This approval is based on positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant improvement in progression-free survival compared to standard treatments.
Key points
- FDA approval of Jaypirca for first-line CLL/SLL treatment.
- No significant market-moving news in the past 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
